Indiana State Police collected more than a ton of expired and unwanted prescription medications Oct. 27 as part of the national “Prescription Drug Take Back” initiative sponsored by the U.S. Drug Enforcement Administration.
The crisis has been years in the making, and the job of wrestling it to the ground has grown into a massive task. No one is yet predicting when the state will be able to declare victory.
Look at the future prospects, not the losses, says the CEO of a newly listed Chinese biotech company that’s developing anti-cancer drugs with Indianapolis-based Eli Lilly and Co.
President Donald Trump said he was “taking aim at the global freeloading that forces American consumers to subsidize lower prices in foreign countries through higher prices in our country.”
President Donald Trump is linking the drug prices Americans complain about to one of his longstanding grievances: foreign countries the president says are taking advantage of U.S. research breakthroughs.
The experimental drug eased arthritis pain in hard-to-treat patients without major safety concerns, a key step in creating a new class of medications that may one day offer an alternative to narcotics.
The drug industry's main trade group said drug companies are only willing to disclose the prices on their websites, not in commercials, and they'll start doing that next spring.
An Indianapolis-based company has signed a deal with national mail-order pharmacy GoGoMeds that officials project will help double its local workforce—to about 250—within five years.
Eli Lilly and Co.’s stock jumped Thursday after midstage research on an experimental diabetes drug showed significant weight loss in patients. The news took a toll on shares of rival Novo Nordisk.
Visits to emergency rooms in Indiana for drug overdoses are falling, and doctors are writing fewer prescriptions for opioid painkillers, Jim McClelland said Friday.
Eli Lilly and Co. received clearance Thursday from U.S. regulators for a new migraine drug that will be the third in a promising class of therapies for patients who suffer from the recurrent, painful headaches.
The competition for the multi-billion dollar migraine market is set to heat up with the FDA expected to decide on Lilly’s migraine therapy next month.
The Indianapolis medical-software firm recently raised $10 million in venture funding and is launching two major products in one month.
Overdose deaths in Indiana rose 18 percent last year compared with 2016 and 37 percent over 2015. A vast majority of the overdoses were caused by opioids.
A boom in major U.S. pharmaceutical stocks is creating a swarm of activity around an exchange-traded fund tracking major drugmakers like Eli Lilly and Co.
After decades of being starved of innovative treatments for serious conditions like cancer, diabetes and kidney disease, China’s 1.4 billion people are becoming a prime target for Eli Lilly and other pharmaceutical companies.
Dr. Dan Skovronsky needs to deliver on the drugmaker’s audacious goal of launching 20 new medicines by 2023.
While the ultimate outcome remains far from certain, the study is a bright spot—if a tenuous one—in the search for a treatment for Alzheimer’s, where more than 100 experimental drugs have failed.
The pharmaceutical company said the 130,000-square-foot building will allow scientists to collaborate better on research for small molecules and synthetic peptides.
An independent data-monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer’s and the other for mild dementia related to the disease.
